

FATIGUE SLEEPINESS ND AGING Lina Fine, MD 10/25/2024

Disclosures


No financial conflicts of interest


First steps





Peripheral fatigue: repeated muscle movements decrease over time






Multidimensional Model of Fatigue vs Age

- Localized nodes (regions)
- Insula response to salient events
- -Striatum motivation
- Edges (connections)
- -Striatum- Prefronal Cortex
- (Perception of fatigue)
- Large scale networks
- Information processing efficiency
- Posterior to Anterior Shift (PASA)
- Frontal regions neural compensation

Lin V, 2023




С

Lin F, 2023

-

Sleep and Fatigue localization



- Fatigue and poor sleep do not localize to the same areas
- Fatigue leads to poor sleep
- Fatigue: primary motor cortex (precentral gyrus), right posterior cingulat cortex, fronto-parietal network
- Poor sleep quality: left intraparietal sulcus


CENTRAL FATIGUE

 The failure to initiate and/or sustain attentional tasks and physical activities requiring self motivation



- Tasks of cognitive vigilance (effort) rather than those performed over prolonged period of time
- Patients may report fatigue and low performance with no objective performance difference (Parmenter, 2003)
- Perceived interference with daily activities

Subjective experience of fatigue



- subjective "feeling" of lacking energy vs objective measured (muscular, cardiovascular)
- What patients say vs. what they mean
- Cognitive fatigue is not cognitive impairment
- Experience
 - during sustained mental effort?
 - After mental exertion?
 - Alertness and vigilance?
 - Is impact on cognitive function or everyday life?

Primary vs. Secondary Fatigue

Primary causes

- Grey matter atrophy (hippocampal) correlation
- Hypometabolism (fMRI) in prefronal, premotor cortices
- Basal ganglia (connection to limbic system cortically driven voluntary activities)

Secondary causes

- Sleep related (OSA, RLS, insomnia, nocturia)
- Mood disorders (depression, anxiety)
- Medications
- Vitamin deficiencies
- Anemia
- Autoimmune and endocrine disorders
- Deconditioning, diet

Sample PROMIS Fatigue Short Form

	In the past 7 days …	Never	Rarely	Some- times	Often	Always
FATEXP	How often did you feel tired?			3	4	5
FATEXP	How often did you experience extreme exhaustion?			3	— 4	5
FATEXP	How often did you run out of energy?			3	4	5
FATIMP 33	How often did your fatigue limit you at work (include work at home)?		D 2	_ 3	D 4	5
FA TIMP 30	How often were you too tired to think clearly?		 2	_ 3	4	5
FA TIMP 21	How often were you too tired to take a bath or shower?			_ 3	— 4	D 5
FA TIMP 40	How often did you have enough energy to exercise strenuously?		D 2	D 3	4	5

PROMIS Patient-Reported Outcomes Measurement Information System Dynamic Tools to Measure Health Outcomes From the Patient Perspective

SCALES PROMIS - DOMAIN FOCUSED, NOT DISEASE FOCUSED

Domain is a feeling, function or perceptions we want to measure

Sleep and fatigue

- Fatigue correlates with worse sleep quality (Ruiz-Rizzo, 2022)
- Sleepiness does increase with age, but not fatigue
- Fatigue does not serve a basic homeostatic role (unlike sleep)
- Causes of poor sleep:
 - Obstructive sleep apnea (central OSA rarely)
 - Restless legs syndrome
 - Pain
 - Hormonal changes
 - Anxiety
 - Medications and substances

MOOD DISORDERS


- Major depressive disorder
 - Negative self evaluation, lack of motivation, anhedonia
 - Sleep disruption
 - Scales (PHQ 2, PHQ 9 pay attention to question 9)
 - May be exacerbated by medications
- Antidepressants can be sedating
 - Less sedating: SSRI: Fluoxetine DNRI: Bupropion
 - Antidepressants are not effective at treating fatigue in neurodegenerative disorders in absence of coexisting depression
- Generalized anxiety disorder (persistent activation, insomnia)
 - GAD 7
 - SSRI, SNRI before benzodiazepine

MEDICATIONS, SUBSTANCES and FATIGUE



- Betablockers
- Muscle relaxants, pain medications
- Benzodiazepines
- SSRIs (some)
- Steroids (effect on sleep)
- Alcohol effect also on sleep
- Cannabis effect on motivation, mood?
- Supplements Ashwaganda, magnesium

SLEEP APNEA



- Snoring (STOP BANG)
- Gasping for air, pauses
- Waking up in panic
- Frequent awakenings *
- Morning headaches**
- Obesity is a risk factor
- Home sleep testing!

STOP BANG

STOP SNORE (loudly) TIRED (daytime) OBSERVED (stop breathing) PRESSURE (Blood pressure)

YES THREE OR MORE TIMES

BANG

BMI (greater than 35)
AGE (over 50)
Neck (circumference 40 cm+)
GENDER (male)

= HIGH RISK OF OSA

RESTLESS LEGS SYNDROME

- 1. Urge to move: irresistible, involves legs but may involve arms and trunk
- 2. Worsening AT REST (body position should not matter)
- 3. Relief with movement (no symptoms during movement)
- 4. Worsening in the evening or at night
- 5. "Achiness", "jumpiness", "crawliness", "itchiness"

RLS TREATMENT

- Check: Ferritin
 - Therapy target ferritin >75 nG/mL (AAN guideline) [normal >15]
- Avoid: Nicotine, Caffeine, Alcohol
 - TCAs and SSRIs/SNRIs nighttime
 - Antihistamines
 - Reglan, Compazine
 - Caution with SSRIs/SNRIs and Antipsychotics
- Treatment
 - Dopamine agonists: Pramipexole, Ropinirole, Rotigotine patch
 - Most common side effect is nausea (10-40%)
 - AUGMENTATION: RLS symptoms worsen frequency, duration, body parts affected, intensity
 - Horizant (Gabapentin Enacarbil) Gabapentin Prodrug
 - Pregabalin

Pharmacological interventions and supplements

- Modafinil/Armodafinil
- Stimulant (methylphenidates, amphetamines)
- Activating antidepressants (if mood symptoms are present)
 - DNRI: Bupropion
 - SSRI: Fluoxetine, Escitalopram
- Supplements: Vitamin B12
 - Only if it is in the lower range of normal (200-1000 mG/L)
 - Use sublingual formulations/ injections/intranasal
- Iron deficiency (ferritin level; % saturation)
- Vitamin D

AITERNATIVES TO MEDICATIONS

Journal of Clinical and Translational Research 2021; 7(4): 575-620



Journal of Clinical and Translational Research

Journal homepage: http://www.jctres.com/en/home



REVIEW ARTICLE

The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review

John E. Lewis^{1*}, Jillian Poles², Delaney P. Shaw³, Elisa Karhu⁴, Sher Ali Khan⁵, Annabel E. Lyons⁶, Susana Barreiro Sacco⁷, H. Reginald McDaniel⁸

¹Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA, ²Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ³Institute of Human Nutrition, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA, ⁴Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA, ⁵Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA, ⁶School of Nursing and Health Studies, University of Miami, Coral Gables, FL, USA, ⁷Department of Internal Medicine, Mount Sinai Medical Center Miami Beach, FL, USA, ⁸Wellness Quest, LLC, Grand Prairie, TX, USA

ARTICLE INFO

Article history Received: January 24, 2021 Revised: June 17, 2021 Accepted: July 09, 2021 Published online: August 4, 2021

Key words:

Alzheimer's disease cognitive function cognitive impairment memory nutrients phytonutrients

**Corresponding author:* John E. Lewis, PhD Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1120 NW, 14th Street, Suite #1482A (D28), Miami, FL 33136, USA. Phone: +1 305-243-6227, Fax: +1 305-243-1619 E-mail: jelewis@miami.edu

© 2021 Lewis, *et al.* This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ bync/4.0/), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT


Background and Aim: Brain health is becoming more important to the average person as the number of people with cognitive impairments, such as Alzheimer's disease (AD), is rising significantly. The current Food and Drug Administration-approved pharmacotherapeutics for dementia neither cure nor halt cognitive decline; they just delay the worsening cognitive impairment. This narrative review summarizes the effects of nutrients and phytonutrients on cognitive function.

Methods: A comprehensive literature search of PubMed was performed to find clinical trials in humans that assessed the effects of nutrients and phytonutrients on cognitive function published in English between 2000 and 2021. Six independent reviewers evaluated the articles for inclusion in this review.

Results: Ninety-six articles were summarized in this narrative review. In total 21 categories of nutrients and phytonutrients were included, i.e., α -lipoic acid, *Bacopa monnieri*, B vitamins, cholinergic precursors, vitamin D, vitamin E, *Ginkgo biloba*, ginseng, lion's mane mushroom, N-acetyl cysteine, omega-3 fatty acids, aloe polysaccharides, *Rhodiola rosea*, rosemary, saffron, tart cherries, turmeric, wild yam, *Withania somnifera*, xanthines, and zinc. Particular noteworthy effects on cognition included memory, recollection, attention, intelligence, vocabulary, recognition, response inhibition, arousal, performance enhancement, planning, creative thinking, reaction time, vigilance, task switching, orientation to time, place, and person, reading, writing, comprehension, accuracy, learning, information processing speed, executive function, mental flexibility, daily functioning, decrease in mental fatigue, and freedom from distractibility. Some nutrients and phytonutrients also improved mood and contentedness and reduced anxiety and the need for caregiving. These effects are not completely consistent or ubiquitous across all patient populations or health statuses. Adverse effects were minimal or nonexistent.

Conclusion: Due to the growing population of people with cognitive impairment and the lack of effective pharmacotherapeutics, it is prudent for those afflicted or their caregivers to find alternative treatments. Our narrative review shows that many of these nutrients and phytonutrients may be promising for treating some aspects of cognitive impairment, especially for people afflicted with AD. **Relevance for Patients:** As demonstrated in a number of clinical trials, healthy adults and patients with various health challenges (e.g., AD, mild cognitive impairment, multiple sclerosis, and Parkinson's disease) exhibiting a wide range of severity in cognitive defects would be best served to consider multiple nutrients and phytonutrients to improve aspects of their cognitive function.

Behavioral approaches to fatigue management



- Rewarded behavior leads to decrease in task fatigue
- Intrinsically rewarding tasks (the flow)
- Exercise aerobic more than resistance exercise improves fatigue
- Light therapy (?)



THANK YOU!

linafinemd@gmail.com